olfactory receptor family 1 subfamily J member 2Genealiases: HG152 · HSA5 · OR1J3 · OR1J5 · OR9-19 · OST044
Q-omics provides the consensus-scored OR1J2 profile across patient tissues and cancer cell-line models. OR1J2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, OR1J2 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, OR1J2 RNA expression shows 6,229 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, HNSC, and THYM as cancer lineages where OR1J2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR1J2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR1J2 survival associations across molecular data types. OR1J2 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR1J2 RNA expression–survival associations across cancer types. High OR1J2 expression shows unfavorable associations in CESC, LIHC, PAAD, MESO, KIRC and LUSC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify CESC as the clearest survival context for OR1J2 RNA expression.
This table summarizes OR1J2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR1J2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR1J2 shows higher tumor expression in HNSC, BRCA, LIHC, BLCA and LUAD. The HNSC box plot shows higher OR1J2 RNA expression in tumor versus normal tissue (log2 FC = +0.033, t-test p = .002).
This table shows molecular features associated with OR1J2 in patient tissues and cancer cell lines. In patient samples, OR1J2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, OR1J2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
